Department of Orthopaedic Surgery, Nagoya University Graduate School and School of Medicine, Nagoya, Japan.
Publication
Summary
This study aimed to determine the significance of CTNNB1 (β-catenin) mutations in predicting the treatment outcome in patients with desmoid tumors treated with meloxicam, a cyclooxygenase-2 (COX-2) selective inhibitor. Between 2003 and 2012, consecutive thirty-three patients with extra-peritoneal sporadic desmoid tumors were prospectively treated with meloxicam as the initial systemic medical therapy. The correlation between the efficacy of meloxicam treatment and status of CTNNB1 mutations was analyzed. The CTNNB1 mutation status was of significant prognostic value for meloxicam treatment in patients with sporadic desmoid tumors.
Stay Up to Date as We Uncover More About Desmoid Tumors
